Download Library

 
 
 
Download Library
Document Type
Interim Report for the Nine Months Ended September 30, 2016
pdf
715.6 KB
Q3 2016 Results Podcast
MP3
23.5 MB
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
PDF
988.3 KB
Investor Fact Sheet
PDF
723.4 KB
Interim Report First Half 2016
pdf
527.7 KB
First Half 2016 Results Presentation
PDF
247.8 KB
First Half 2016 Results Podcast
MP3
27.2 MB
Management of transaminase elevations associated with idelalisib - EHA poster regarding ofatumumab submitted by Gilead - June 2016 (Ghia)
PDF
1.5 MB
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study
PDF
1.4 MB
Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL - EHA E-Poster regarding ofatumumab submitted by Gilead - June 2016 (Ghia)
PDF
270.2 KB
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA Poster - June 2016 (Casneuf)
PDF
484.0 KB
Daratumumab monotherapy compared with real-world control data in heavily pretreated patients with multiple myeloma - EHA E-Poster - June 2016 (Diels)
PDF
539.8 KB
Daratumumab plus Lenalidomide & dexamethasone Phase 3 POLLUX data - EHA presentation - June 2016 (Dimopoulos)
PDF
1.3 MB
Goldman Sachs 37th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US - June 2016
PDF
2.3 MB
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in multiple myeloma (PAVO) - ASCO poster - June 2016 (Nahi)
PDF
4.8 MB
Cost per median overall month of survival in multiple myeloma patients with greater than or equal to 3 lines of therapy - ASCO poster - June 2016 (Maiese)
PDF
198.7 KB
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - ASCO presentation - June 2016 (Palumbo)
PDF
1.5 MB
Updated Phase 3 results of idelalisib in combination with ofatumumab for previously treated CLL- EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Robak)
URL
N/A
Discontinuation of idelalisib due to disease progression in relapsed and refractory CLL - EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Brown)
URL
N/A
Daratumumab plus bortezomib & dexamethasone Phase 3 CASTOR data - EHA abstract - May 2016 (Palumbo)
URL
N/A
Evaluation of CLL-IPI score in r/r CLL in idelalisib Phase 3 studies - EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Soumerai)
URL
N/A
Ofatumumab vs rituximab Phase 3 HOMER data - EHA abstract - May 2016 (Maloney)
URL
N/A
Management of transaminase elevations associated with idelalisib - EHA abstract regarding ofatumumab submitted by Gilead - May 2016 (Ghia)
URL
N/A
Pharmacodynamic relationship between natural killer cells and daratumumab exposure in multiple myeloma - EHA abstract - May 2016 (Diels)
URL
N/A
Estimating cost effectiveness of ofatumumab for double-refractory CLL - EHA abstract - May 2016 (Hatswell)
URL
N/A

Page: First Previous
1
2
3
4
5
6
7
8
...
17
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Årsregnskab 2001
PDF
429.6 KB
Kvartalsrapport - 3. kvartal 2000
PDF
59.2 KB
Årsregnskab 2000
PDF
592.8 KB
Page: First Previous
1
2
3
4